Pfizer's Kindler Joins BIO Board of Directors

WASHINGTON, D.C. (February 20, 2007) -- The Biotechnology Industry Organization (BIO) today announced the election of Pfizer Chairman and CEO Jeffrey B. Kindler to BIO’s Board of Directors. Kindler will replace Pfizer Vice President of Corporate Policy and Strategic Management Fred Telling, who had served on the BIO Board for eleven years and is retiring from Pfizer this year.

“We are thrilled to welcome Jeff to our Board of Directors,” stated BIO President and CEO Jim Greenwood. “He brings a wealth of experience. His insights and guidance will be of great help as we continue in our mission to grow the biotechnology industry.”

Mr. Kindler was appointed CEO and elected to Pfizer’s Board of Directors in 2006. He first joined Pfizer in 2002 as Executive Vice President and General Counsel, with responsibility for Pfizer’s Legal Division, where he led the company’s worldwide legal, compliance, communications, government relations, corporate citizenship, policy development and global security groups. He was named Vice Chairman in 2005, joining the company’s four-person Executive Committee and assuming responsibility for Pfizer’s Corporate Affairs Division.

Mr. Kindler holds a BA from Tufts University as well as a JD from Harvard, where he was an editor of the Harvard Law Review. He began his legal career as an attorney at the Federal Communications Commission. He later served as law clerk to U.S. Supreme Court Justice William J. Brennan, Jr. before joining the law firm of Williams & Connolly as a partner.

Kindler began his corporate career at General Electric and later served in executive positions with the McDonald’s Corporation.

During his corporate career, Jeff Kindler has been recognized for his leadership in the areas of pro bono legal services, diversity, and corporate social responsibility by groups ranging from Outward Bound to the Minority Corporate Counsel Association.

He currently serves on the boards of trustees of Tufts University, the John F. Kennedy Center for the Performing Arts, Business Roundtable, Manhattan Theatre Club, the Council on Competitiveness, New York Philharmonic, the Partnership for New York City, The Business Council, and Ronald McDonald House Charities, as well as serving as the Chairman of the U.S. - Japan Business Council.

About BIO

BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and 31 other nations. BIO members are involved in the research and development of healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the annual BIO International Convention, the world’s largest biotechnology conference and exhibition.

Upcoming BIO Events